Anti-PIAS1 antibody
Specifications
| Product Cat#: | AB-07-2015 |
| Product type: | Primary antibody |
| Antigen: | PIAS1 |
| Immunogen: | A synthetic peptide derived from human PIAS1. The exact amino-acid sequence is proprietary. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | ELISA (1:10000); Western Blot (1:500-1:2500); Immunohistochemistry (1:50-1:100) |
| Reactivity: | Human, Mouse |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+ ), pH 7.4, 0.02% sodium azide and 50% glycerol |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | AR interacting protein, DDXBP1, DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1, DEAD/H box-binding protein 1, GBP, GU/RH-II, Gu-binding protein, RNA helicase II-binding protein, Protein inhibitor of activated STAT protein 1, Protein inhibitor of activated STAT 1, Protein inhibitor of activated STAT-1 |
Target information
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Sumoylates PML (at’Lys-65′ and ‘Lys-160’) and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity).
Provider
Erpantech Laboratory
